A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2006
12/06/2006	CN1287816C Chinese patent medicine for treating senile dementia and its preparing process
12/06/2006	CN1287800C Medicine for regulating nerve system, treating epilepsia disease
12/06/2006	CN1287799C Bean curd fruit glycocide softcapsule
12/06/2006	CN1287791C Combination of semisolid framework preparation of nimodipine
12/06/2006	CN1287788C Prepn and product of oxiracetam powder for injection
12/06/2006	CN1287780C Orodispersible pharmaceutical composition of agomelatine
12/06/2006	CN1287675C Pueraria flower tea capable of dispelling effects of liquor
12/05/2006	USRE39419 Estrogen agonist/antagonist metabolites
12/05/2006	US7145037 Adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them
12/05/2006	US7145009 Pirazino(aza)indole derivatives
12/05/2006	US7144997 Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
12/05/2006	US7144918 Enzyme inhibitors; anticancer agents
12/05/2006	US7144915 Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
12/05/2006	US7144912 drugs such as (4-methoxy-5-(1H-indol-2yl-methylene)-2,2'-bi-1H-pyrrole) used as anticarcinogenic or antitumor agents
12/05/2006	US7144910 hydrolase enzyme antagonists such as N-{(6S,9R,11R)-2-[5-4-fluoroophenyl)-1-methyl-1H-pyrazol-3-yl]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-yl}-N'-(2,2,2-trifiuoroethyl)sulfamide that inhibit processing of amyloid precursor protein, useful in treating or preventing Alzheimer's disease
12/05/2006	US7144908 Prophylaxis, therapy of respiratory system disorders
12/05/2006	US7144902 Prodrugs of thrombin inhibitors
12/05/2006	US7144898 Indole derivatives for the treatment of depression and anxiety
12/05/2006	US7144897 Substituted amide compound containing hydroxy and amino groups; useful for treating Alzheimer's disease and other similar diseases
12/05/2006	US7144896 heterocyclic imines such as 3-[6-(1-Methanesulfonyl-1-methyl-ethyl)-quinolin-8-yl]-N-[6-(4-methylsulfanyl-phenyl)-pyridin-3-yl]-benzamide, used as phosphodiesterases (pde4) inhibitors; side effect reduction
12/05/2006	US7144888 Vanilloid receptor ligands and their use in treatments
12/05/2006	US7144887 Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition
12/05/2006	US7144884 E.g., 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or piperazine or the hydrochloride or oxalate; treating depression, anxiety disorder, and obsessive compulsive disorder.
12/05/2006	US7144883 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders
12/05/2006	US7144882 Central nervous system disorders; psychological disorders; inflammatory bowel disorders
12/05/2006	US7144873 Therapy for anticancer agents, blood disorders; dissolving in nonaqueous solvent
12/05/2006	US7144871 Partial and full agonists of A1 adenosine receptors
12/05/2006	US7144707 Determination of risk and treatment of complications of prematurity
12/05/2006	CA2396458C Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
12/05/2006	CA2387531C Purine derivatives
12/05/2006	CA2360313C Glucocorticoid receptor modulators
12/05/2006	CA2326630C Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof
12/04/2006	CA2558746A1 Use of paliperidone for the treatment of substance abuse
12/02/2006	CA2510119A1 Modified-release composition of at least one form of venlafaxine
11/2006
11/30/2006	WO2006128142A2 Inhibitors of cytosolic phospholipase a2
11/30/2006	WO2006127899A2 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
11/30/2006	WO2006127898A2 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
11/30/2006	WO2006127574A2 Method for the treatment of noise phobia in companion animals
11/30/2006	WO2006127418A1 Scopolamine for the treatment of depression and anxiety
11/30/2006	WO2006126939A1 Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
11/30/2006	WO2006126938A1 Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
11/30/2006	WO2006126718A1 Pyrazolopyrimidine derivative
11/30/2006	WO2006126706A1 Prophylactic/therapeutic agent for psychotic disorder such as bipolar mood disorder and schizophrenia, screening method for the same, and method for determination of risk for the development of the disease
11/30/2006	WO2006126682A1 Vaccine for prevention/treatment of alzheimer disease
11/30/2006	WO2006126625A1 Pharmaceutical comprising pyrazolone derivative
11/30/2006	WO2006126514A1 Arylacetate derivative having isoxazole skeleton
11/30/2006	WO2006126505A1 Stat function inhibitor and application thereof
11/30/2006	WO2006125930A1 Composition for the treatment of multiple sclerosis
11/30/2006	WO2006125887A1 5h-pyrido[4,3-b]indole derivative compounds and uses thereof as medicine for treating polyglutamin neurodegenerative diseases
11/30/2006	WO2006125812A1 Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament
11/30/2006	WO2006125807A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125805A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125803A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125622A1 Crystalline form of benzazepinium maleate derivative
11/30/2006	WO2006125324A1 Treatment of protein folding disorders
11/30/2006	WO2006113261A3 Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
11/30/2006	WO2006067607A3 Polyacetylen compounds isolated from cussonia
11/30/2006	WO2005089753A3 Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
11/30/2006	US20060270839 Crystallization of IGF-1
11/30/2006	US20060270838 covalent heterodimer of two different neurotrophins; which have multiple neurotrophic specificities; use in treatment of nervous system disorders
11/30/2006	US20060270832 Novel x-conotoxin peptides (-II)
11/30/2006	US20060270729 Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof
11/30/2006	US20060270713 3-Aminopyrrolidines as inhibitors of monoamine uptake
11/30/2006	US20060270712 contains 4-[ alpha -hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid; prophylaxis, hypomyelination, dysmyelination or demyelination; myelin-associated glycoprotein (MAG)
11/30/2006	US20060270699 Stabilization of hypoxia inducible factor (HIF) alpha
11/30/2006	US20060270691 Purine derivatives as purinergic receptor antagonists
11/30/2006	US20060270690 N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto
11/30/2006	US20060270683 Polymorphs of aripiprazole
11/30/2006	US20060270681 Pyridazine derivatives
11/30/2006	US20060270679 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/30/2006	US20060270676 Hydrazono-malonitriles
11/30/2006	US20060270665 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
11/30/2006	US20060270660 Processes for preparing substituted pyrimidines
11/30/2006	US20060270656 Substituted piperazines of azepines, oxazepines and thiazepines
11/30/2006	US20060270649 Azetidine derivatives, their preparation and medicaments containing them
11/30/2006	US20060270646 Jnk inhibitors
11/30/2006	US20060270599 Inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
11/30/2006	US20060269996 Human voltage gated sodium channel beta1A subunit and methods of use
11/30/2006	US20060269959 Sequences of an Ih ion channel and use thereof
11/30/2006	US20060269627 Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia
11/30/2006	US20060269613 Composition containing nanoparticles containing water-soluble basic drug encpsulated therein
11/30/2006	US20060269604 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
11/30/2006	US20060269603 Controlled release tramadol formulations
11/30/2006	US20060269568 Reduction of embryonic neural tube defects by pre-or early-administration of germination-activated sporoderm-broken ganoderma lucidum spores to pregnant female
11/30/2006	US20060269565 Administering a polypeptide fused to an Fc, has T-cell proliferation inhibiting activity to treat autoimmune encephalomyelitis
11/30/2006	US20060269539 Genetic engineering; Alzheimer's agents; anticancer agents
11/30/2006	US20060269487 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
11/30/2006	CA2610025A1 Scopolamine for the treatment of depression and anxiety
11/30/2006	CA2609980A1 Treatment of protein folding disorders
11/30/2006	CA2609747A1 Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphthalene derivatives modulating the 5ht6 receptor
11/30/2006	CA2609735A1 Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphthalene derivatives modulating the 5ht6 receptor
11/30/2006	CA2609662A1 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use
11/30/2006	CA2609489A1 Crystalline form of benzazepinium maleate derivative
11/30/2006	CA2609393A1 (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
11/30/2006	CA2609369A1 Composition for the treatment of multiple sclerosis
11/30/2006	CA2609215A1 Method for the treatment of noise phobia in companion animals
11/30/2006	CA2608153A1 Thiazole derivatives for use as p13k modulators
11/30/2006	CA2608143A1 Thiazole derivatives and use thereof
11/30/2006	CA2607857A1 Inhibitors of cytosolic phospholipase a2
11/30/2006	CA2607385A1 Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases

1 ... 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 ... 1833